PhenoPath launches first-ever NGS assay
Please read the attached letter for additional information.
We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Company News
News & Info » Company News
PhenoPath conference March 7th
Please read the attached letter regarding the PhenoPath conference scheduled for March 7th, 2019
RAS Launch Notification
PhenoPath is pleased to announce the launch of extended RAS gene testing. Beginning June 5, 2017, PhenoPath will offer in-house KRAS and NRAS testing that complies with the joint guidelines recently issued by ASCP, CAP, AMP and ASCO
Roche cobas® EGFR Plasma Mutation Test
PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma.
Roche cobas® EGFR Mutation Test
PhenoPath is pleased to offer the Roche cobas® EGFR Mutation Test (v2), the only FDA-approved IVD assay for the detection of T790M, Exon 19 deletion, and L858R EGFR mutations in DNA isolated from formalin fixed paraffin embedded tumor tissue (FFPE) or in cell-free/circulating tumor DNA from plasma.
PD-L1 IHC 28-8 pharmDx
PhenoPath is pleased to announce the availability of the PD-L1 IHC 28-8 pharmDx, the only FDA-approved test for PD-L1 expression associated with enhanced survival with OPDIVO® (nivolumab) for non-squamous NSCLC.
PD-L1 IHC 22C3 pharmDx
PhenoPath is proud to announce the release of FDA-approved PD-L1 IHC 22C3 pharmDx, for the semi-quantitative assessment of PD-L1 expression in non-small cell lung carcinomas (NSCLC).
Lung Fluid Versus Tissue Biopsy for Mesothelioma Diagnosis
The pathologists from PhenoPath and the University of British Columbia found that certain genetic alterations were seen just as often in the fluid samples of mesothelioma patients as they were in tissue samples.
PhenoPath Adopts 2013 Updated ASCO-CAP HER2 Testing Guidelines in Breast Cancer
PhenoPath is one of the first labs in the US to adopt all the complex changes of the 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO-CAP) HER2 Testing Guideline updates in breast cancer.
PhenoPath is pleased to announce MSI by PCR
Hereditary non-polyposis colorectal carcinoma (HNPCC), also known as Lynch Syndrome, is an autosomal dominant hereditary cancer syndrome associated with germline mutations in one of the mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2).
FDA-approved Therascreen® KRAS mutation in vitro diagnostic (IVD) test for colorectal adenocarcinoma
PhenoPath Laboratories is pleased to announce that we are offering the FDA-approved Therascreen® KRAS mutation in vitro diagnostic (IVD) test for colorectal adenocarcinoma.
PhenoPath Laboratories Releases the 7th Edition of Its “Pathology Reference Guide”
PhenoPath Laboratories has released the much-awaited 7th Edition of its Pathology Reference Guide, a comprehensive overview of all the immunohistochemistry, flow cytometry, and molecular (PCR based and FISH based) testing offered by PhenoPath Laboratories.
PhenoPath Launches New Website
PhenoPath Laboratories is pleased to announce the launch of their newly designed website: www.phenopath.com, which goes live on Monday, November 19, 2012. The new design advances our mission to provide “Diagnoses you can count on®” by providing our customers access to extensive diagnostic pathology reference and referral resources.
PhenoPath Laboratories Publishes JCO Article on New Breast Cancer Testing Protocol
A new laboratory testing protocol can more accurately identify an important group of breast cancer patients who are most likely to benefit from a “targeted therapy” shown to dramatically improve survival.
PhenoPath Retests Nearly 3,000 Breast Cancer Specimens
Seattle-based PhenoPath Laboratories served as the reference laboratory for a highly anticipated retesting of nearly 3,000 breast cancer specimens from the Province of Quebec, results of which were announced by Quebec Health Minister Yves Bolduc this week.